These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 17437481)

  • 1. Calcineurin inhibitors and rapamycin: cancer protection or promotion?
    Weischer M; Röcken M; Berneburg M
    Exp Dermatol; 2007 May; 16(5):385-93. PubMed ID: 17437481
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Macrolactam immunomodulators for topical treatment of inflammatory skin diseases.
    Bornhövd E; Burgdorf WH; Wollenberg A
    J Am Acad Dermatol; 2001 Nov; 45(5):736-43. PubMed ID: 11606925
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Malignancy concerns of topical calcineurin inhibitors for atopic dermatitis: facts and controversies.
    Thaçi D; Salgo R
    Clin Dermatol; 2010; 28(1):52-6. PubMed ID: 20082951
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Black box warning for topical calcineurin inhibitors and the death of common sense.
    Fleischer AB
    Dermatol Online J; 2006 Oct; 12(6):2. PubMed ID: 17083882
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Teaching old drugs new tricks: reincarnating immunosuppressants as antifungal drugs.
    Blankenship JR; Steinbach WJ; Perfect JR; Heitman J
    Curr Opin Investig Drugs; 2003 Feb; 4(2):192-9. PubMed ID: 12669381
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of immunosuppressive drugs on spontaneous DNA repair in human peripheral blood mononuclear cells.
    Ori Y; Herman-Edelstein M; Zingerman B; Rozen-Zvi B; Gafter U; Malachi T; Gafter-Gvili A
    Biomed Pharmacother; 2012 Sep; 66(6):409-13. PubMed ID: 22795807
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The macrolide immunosuppressants in dermatology: mechanisms of action.
    Marsland AM; Griffiths CE
    Eur J Dermatol; 2002; 12(6):618-22. PubMed ID: 12459545
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Review of the potential photo-cocarcinogenicity of topical calcineurin inhibitors: position statement of the European Dermatology Forum.
    Ring J; Barker J; Behrendt H; Braathen L; Darsow U; Dubertret L; Giannetti A; Hawk J; Hönigsmann H; Kemeny L; Luger T; Meurer M; Murphy G; Peserico A; Ranki A; Reunala T; Saurat J; Sterry W; van de Kerkhof P
    J Eur Acad Dermatol Venereol; 2005 Nov; 19(6):663-71. PubMed ID: 16268869
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Pro- and antitumor effects of the main immunosuppressive drugs used in the clinical practice of transplantation].
    Marchini F
    G Ital Nefrol; 2007; 24(2):171. PubMed ID: 17458835
    [No Abstract]   [Full Text] [Related]  

  • 10. Potential new indications of topical calcineurin inhibitors.
    Luger T; Paul C
    Dermatology; 2007; 215 Suppl 1():45-54. PubMed ID: 18174692
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety of topical calcineurin inhibitors for the treatment of atopic dermatitis.
    Munzenberger PJ; Montejo JM
    Pharmacotherapy; 2007 Jul; 27(7):1020-8. PubMed ID: 17594208
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Topical pimecrolimus and tacrolimus and the risk of cancer].
    Sánchez-Pérez J
    Actas Dermosifiliogr; 2007 Jun; 98(5):312-7. PubMed ID: 17555673
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The use of topical calcineurin inhibitors in dermatology: safety concerns. Report of the American Academy of Dermatology Association Task Force.
    Berger TG; Duvic M; Van Voorhees AS; VanBeek MJ; Frieden IJ;
    J Am Acad Dermatol; 2006 May; 54(5):818-23. PubMed ID: 16635663
    [No Abstract]   [Full Text] [Related]  

  • 14. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial.
    Schena FP; Pascoe MD; Alberu J; del Carmen Rial M; Oberbauer R; Brennan DC; Campistol JM; Racusen L; Polinsky MS; Goldberg-Alberts R; Li H; Scarola J; Neylan JF;
    Transplantation; 2009 Jan; 87(2):233-42. PubMed ID: 19155978
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sirolimus in liver transplant recipients with renal dysfunction offers no advantage over low-dose calcineurin inhibitor regimens.
    DuBay D; Smith RJ; Qiu KG; Levy GA; Lilly L; Therapondos G
    Liver Transpl; 2008 May; 14(5):651-9. PubMed ID: 18433069
    [TBL] [Abstract][Full Text] [Related]  

  • 16. mTOR inhibitors: an overview.
    Neuhaus P; Klupp J; Langrehr JM
    Liver Transpl; 2001 Jun; 7(6):473-84. PubMed ID: 11443573
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A retrospective study of conversion from tacrolimus-based to sirolimus-based immunosuppression in orthotopic liver transplant recipients.
    Yu S; He X; Yang L; Ma Y; Zhu X; Ju W; Huang J
    Exp Clin Transplant; 2008 Jun; 6(2):113-7. PubMed ID: 18816237
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Controversies about the use of calcineurin inhibitors in pediatric patients].
    Dello Strologo L
    G Ital Nefrol; 2008; 25(3):317-24. PubMed ID: 18473303
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systemic ciclosporin and tacrolimus in dermatology.
    Madan V; Griffiths CE
    Dermatol Ther; 2007; 20(4):239-50. PubMed ID: 17970889
    [TBL] [Abstract][Full Text] [Related]  

  • 20. What does the CONVERT trial really tell us about conversion from calcineurin inhibitors to sirolimus?
    Hanto DW; Chudzinski R
    Transplantation; 2009 Jan; 87(2):164-5. PubMed ID: 19155968
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.